Sebnem Gursoy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sebnem Gursoy has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Edip Torun
Department of Gastroenterology, Erciyes University, Kayseri, Turkey
3 shared publications- Ahmet Karaman
Department of Gastroenterology, Erciyes University, Kayseri, Turkey
2 shared publications Alper Yurci
Department of Gastroenterology, Erciyes University, Kayseri, Turkey
2 shared publications- Ahmet Emrah Açan
Department of Orthopedics and Traumatology, Faculty of Medicine, Balikesir University, Balikesir, Turkey
1 shared publication - Aydin Unal
University Of Health Sciences Turkey, Istanbul Mehmet Akif Ersoy Thoracic And Cardiovascular Surgery Training And Research Hospital, Cardiovascular Surgery, İstanbul, Turkey
1 shared publication Cengiz Utas
Erciyes University, Department of Nephrology, Kayseri, Turkey
1 shared publication
Latest Publications
- Open Access
- 4 July 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (27) , e43244
Evaluation of the relationship between Hoffa volume and radiological and clinical scoring in the diagnosis and treatment of anterior knee pain: A retrospective observational study
This study aimed to evaluate the relationship between clinical outcomes and Hoffa fat pad (HFP) volume with respect to treatment type: conventional therapy (NSAIDs and topical cold) and intra-articular platelet-rich plasma (PRP). This retrospective study included patients aged 18 to 40 years with anterior knee pain (AKP), positive Hoffa squeeze and extension impingement tests, and no radiological pathology. After applying the inclusion and exclusion criteria, the patients were divided into conventional treatment (n = 28) and PRP (n = 27) groups, with a control group (n = 25) to compare the baseline HFP volume. HFP volume was measured pre- and posttreatment using 3D Slicer software, while clinical outcomes were assessed using Lysholm, Oxford Knee, and visual analog scale (VAS) scores. Baseline HFP volumes did not differ significantly between the groups (P = .236). The conventional group showed a significant reduction in HFP volume, from 30.8 ± 5.9 cm3 to 29.5 ± 5.7 cm3 (P = .002), while the PRP group saw an increase from 28.0 ± 5.3 cm3 to 29.9 ± 6.3 cm3 (P = .001). Baseline VAS scores were higher in the PRP group (7.1 ± 0.9 vs 6.0 ± 1.0, P < .001), with posttreatment VAS scores improving in both groups (PRP: 3.0, P < .001; Conventional: 1.5, P < .001). Lysholm and Oxford scores increased significantly posttreatment (P < .001), although no correlation was found between HFP volume and these scores. These findings suggest Hoffa volume may influence AKP, although volume changes do not directly correlate with functional improvement, indicating that other pathophysiological factors may play a role. These findings highlight the need for further studies to understand HFP’s role of HFP in AKP and inform targeted treatments.
- 4 July 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (27) , e43244
Open AccessEvaluation of the relationship between Hoffa volume and radiological and clinical scoring in the diagnosis and treatment of anterior knee pain: A retrospective observational study
This study aimed to evaluate the relationship between clinical outcomes and Hoffa fat pad (HFP) volume with respect to treatment type: conventional therapy (NSAIDs and topical cold) and intra-articular platelet-rich plasma (PRP). This retrospective study included patients aged 18 to 40 years with anterior knee pain (AKP), positive Hoffa squeeze and extension impingement tests, and no radiological pathology. After applying the inclusion and exclusion criteria, the patients were divided into conventional treatment (n = 28) and PRP (n = 27) groups, with a control group (n = 25) to compare the baseline HFP volume. HFP volume was measured pre- and posttreatment using 3D Slicer software, while clinical outcomes were assessed using Lysholm, Oxford Knee, and visual analog scale (VAS) scores. Baseline HFP volumes did not differ significantly between the groups (P = .236). The conventional group showed a significant reduction in HFP volume, from 30.8 ± 5.9 cm3 to 29.5 ± 5.7 cm3 (P = .002), while the PRP group saw an increase from 28.0 ± 5.3 cm3 to 29.9 ± 6.3 cm3 (P = .001). Baseline VAS scores were higher in the PRP group (7.1 ± 0.9 vs 6.0 ± 1.0, P < .001), with posttreatment VAS scores improving in both groups (PRP: 3.0, P < .001; Conventional: 1.5, P < .001). Lysholm and Oxford scores increased significantly posttreatment (P < .001), although no correlation was found between HFP volume and these scores. These findings suggest Hoffa volume may influence AKP, although volume changes do not directly correlate with functional improvement, indicating that other pathophysiological factors may play a role. These findings highlight the need for further studies to understand HFP’s role of HFP in AKP and inform targeted treatments.
- 1 January 2012
- Published by SAGE Publications in The Journal of Alternative and Complementary Medicine
- Vol. 18 (1) , 65-68
Endoscopic Topical Application of Ankaferd Blood Stopper ® in Gastrointestinal Bleeding
Aim: This was a prospective study investigating the efficacy of Ankaferd Blood Stopper® (ABS), an herbal preparation, in patients with upper gastrointestinal (UGI) bleeding. Materials and methods: A total of 30 patients (22 male, 8 female) who had UGI bleeding (with differing causes) were included in the study. ABS was used to stop the bleeding. Results: Primary hemostasis was achieved in 26 of the 30 cases. Conclusions: ABS is an effective and safe agent to use in patients with UGI bleeding.
- 1 January 2012
- Published by SAGE Publications in The Journal of Alternative and Complementary Medicine
- Vol. 18 (1) , 65-68
Endoscopic Topical Application of Ankaferd Blood Stopper ® in Gastrointestinal Bleeding
Aim: This was a prospective study investigating the efficacy of Ankaferd Blood Stopper® (ABS), an herbal preparation, in patients with upper gastrointestinal (UGI) bleeding. Materials and methods: A total of 30 patients (22 male, 8 female) who had UGI bleeding (with differing causes) were included in the study. ABS was used to stop the bleeding. Results: Primary hemostasis was achieved in 26 of the 30 cases. Conclusions: ABS is an effective and safe agent to use in patients with UGI bleeding.
- 1 October 2010
- Published by SAGE Publications in The Journal of Alternative and Complementary Medicine
- Vol. 16 (10) , 1027-1028
Efficacy of Ankaferd Blood Stopper in Postpolypectomy Bleeding
- 1 October 2010
- Published by SAGE Publications in The Journal of Alternative and Complementary Medicine
- Vol. 16 (10) , 1027-1028
Efficacy of Ankaferd Blood Stopper in Postpolypectomy Bleeding
- Open Access
- 1 February 2010
- Published by Taylor & Francis in Renal Failure
- Vol. 32 (1) , 74-77
Occult HBV Infection in Continuous Ambulatory Peritoneal Dialysis and Hemodialysis Patients
Aim. Occult hepatitis B virus (HBV) infection can be defined as the presence of HBV DNA in the liver and/or blood in the absence of detectable serum hepatitis B surface antigen (HBs Ag). There is a high prevalence of occult HBV infection in dialysis patients. This study investigated the prevalence of occult HBV infection in continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis (HD) patients and compared the prevalence of occult HBV infection in dialysis patients either with or without hepatitis C virus (HCV) infection. Methods. In this cross-sectional study, 71 CAPD patients and 71 HD patients were evaluated. HBV DNA testing was performed by polymerase chain reaction (PCR). We recorded general characteristics of the patients, duration of dialysis, HBs Ag, antibody to hepatitis B surface antigen (anti-HBs), antibody to hepatitis B core antigen (anti-HBc), anti-HCV antibody (anti-HCV), HCV RNA, serum alanine aminotransferase (ALT), and aspartate aminotransferase levels (AST). Results. Twelve (16.9%) of the 71 HD patients and seven (9.8%) of the 71 CAPD patients were HBV DNA-positive. A statistically significant difference was not observed in the groups. Anti-HCV was negative and AST and ALT levels were normal in all of the HBV-DNA positive patients. Viral loads were low in both groups. Conclusion. This is the first study that analyzes occult HBV prevalence in CAPD patients. We conclude that the prevalence of the occult HBV may be common in CAPD patients as in HD patients, and HCV positivity is not a contributing factor to occult HBV infection in dialysis patients.
- 1 February 2010
- Published by Taylor & Francis in Renal Failure
- Vol. 32 (1) , 74-77
Open AccessOccult HBV Infection in Continuous Ambulatory Peritoneal Dialysis and Hemodialysis Patients
Aim. Occult hepatitis B virus (HBV) infection can be defined as the presence of HBV DNA in the liver and/or blood in the absence of detectable serum hepatitis B surface antigen (HBs Ag). There is a high prevalence of occult HBV infection in dialysis patients. This study investigated the prevalence of occult HBV infection in continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis (HD) patients and compared the prevalence of occult HBV infection in dialysis patients either with or without hepatitis C virus (HCV) infection. Methods. In this cross-sectional study, 71 CAPD patients and 71 HD patients were evaluated. HBV DNA testing was performed by polymerase chain reaction (PCR). We recorded general characteristics of the patients, duration of dialysis, HBs Ag, antibody to hepatitis B surface antigen (anti-HBs), antibody to hepatitis B core antigen (anti-HBc), anti-HCV antibody (anti-HCV), HCV RNA, serum alanine aminotransferase (ALT), and aspartate aminotransferase levels (AST). Results. Twelve (16.9%) of the 71 HD patients and seven (9.8%) of the 71 CAPD patients were HBV DNA-positive. A statistically significant difference was not observed in the groups. Anti-HCV was negative and AST and ALT levels were normal in all of the HBV-DNA positive patients. Viral loads were low in both groups. Conclusion. This is the first study that analyzes occult HBV prevalence in CAPD patients. We conclude that the prevalence of the occult HBV may be common in CAPD patients as in HD patients, and HCV positivity is not a contributing factor to occult HBV infection in dialysis patients.